Nivar v. Protega Pharmaceuticals Inc.Nivar v. Protega Pharmaceuticals Inc.
OPINION & ORDER
ANDREW L. CARTER, JR., United States District Judge:
Plaintiff Jennifer Nivar (“Plaintiff”) brings this action against Defendant Protega Pharmaceuticals, Inc. (“Defendant”) alleging retaliation in violation of the False Claims Act,
BACKGROUND
I. Factual Background
Plaintiff alleges that she worked for Defendant Protega Pharmaceuticals Inc. as a Key Account Manager from 2022 to May 2025. Complaint (“Compl.”) ¶ 9. Plaintiff was responsible for promoting Protega’s drug RoxyBond to doctors for its approved uses. Id. ¶ 11. RoxyBond is a drug containing oxycodone, an opioid used for pain treatment, that is heavily prescribed to patients who are covered by Medicare. Id. ¶¶ 12, 44.
In or about September 2024, Plaintiff learned that two of her colleagues, Specialty Account Manager Chris Schulte and Key Account Manager Jessica Kraszewski, were having a sexual relationship. Id. ¶ 20. In early September 2024, after the global “Pain Week” conference for pain management professionals in Las Vegas, Mr. Schulte confided in Plaintiff that he had slept with Ms. Kraszewski at the recent conference. Id. ¶ 21. Following that revelation, Mr. Schulte frequently updated Plaintiff about his escapades with Ms. Kraszewski. He described the provocative pictures he received from Ms. Kraszewski and the salacious text messages she sent him describing sexual acts she hoped to perform on him. Id. ¶ 22.
Protega promoted Ms. Kraszewski to the position of National Business Director in or about January 2025. Although Plaintiff’s prescription numbers were better than Ms. Kraszewski’s numbers, Protega did not offer Plaintiff the National Business Director role. Id. ¶ 24. In her new role, Ms. Kraszewski was considered part of Protega’s leadership team and senior to both Plaintiff and Mr. Schulte. Id. ¶ 25. Ms. Kraszewski quickly made it apparent that she intended to help her lover, Mr. Schulte, advance in the Company. Id. ¶ 26.
In or about February 2025, Plaintiff attended the North American Neuromodulation Society (“NANS”) conference in Orlando, Florida. At the conference, Plaintiff, Ms. Kraszewski and other Protega Account Managers promoted RoxyBond and educated conference attendants about its uses. Id. ¶ 30. While at the NANS conference, Plaintiff, Ms. Kraszewski, and Account Manager Tracy Sturgis took one of their target providers, Dr. Swartz, out for dinner. Id. ¶ 31. Whenever a pharmaceutical rep entertains prescribing doctors, they are supposed to have a sign-in sheet to
During the meal, Plaintiff alleges Ms. Kraszewski and Dr. Swartz consumed large amounts of alcohol and began interacting in a highly inappropriate manner. Id. ¶ 35. Dr. Swartz congratulated Ms. Kraszewski on her recent promotion and then said, “Please hire a hot woman to replace you. I love when your reps come, they’re always hot.” Id. ¶ 36. Dr. Swartz then asked Ms. Kraszewski, in front of everyone at the table, when she planned on sending his partner, Dr. Russell Feit, more “naked pictures.” Ms. Kraszewski laughed at the comment and feigned surprise. Id. ¶ 37.
The following morning, while Plaintiff and Ms. Sturgis were sitting together in the conference area attending to the Protega booth, Dr. Swartz approached them and reiterated that Ms. Kraszewski had in fact sent his partner naked pictures of herself. Id. ¶ 40. Plaintiff alleges she became extremely concerned that Ms. Kraszewski was, in violation of the Anti-Kickback Statute (“AKS”), inducing providers to prescribe RoxyBond using highly inappropriate tactics. Id. ¶ 41. The AKS bans the exchange of anything of value in return for generating business that involves federal healthcare programs like Medicare and Medicaid. Id. ¶ 42. Compliance with the AKS is a condition of receiving payment from federally-funded healthcare programs, including Medicare. Id. ¶ 43. RoxyBond is heavily prescribed to patients who are covered by Medicare. Id. ¶ 44.
On the Monday following the NANS conference, Plaintiff reported to her direct supervisor, National Business Director Christy Sweet, what she witnessed during the dinner with Dr. Swartz. Plaintiff reported the inappropriate conversation about Ms. Kraszewski sending nude pictures to Dr. Feit, one of Protega’s Key Opinion Leaders, and she also reported that there had not been a sign-in
Approximately one month after the dinner occurred, Ms. Sweet told Plaintiff that at a meeting with top leadership, she saw a fabricated sign-in sheet that Ms. Kraszewski had submitted for the dinner with Dr. Swartz during the NANS conference. Id. ¶ 50. Ms. Sweet said that she not only saw Plaintiff’s forged signature on the sign-in sheet, she also saw the names of several doctors who were not actually present at the dinner. Id. Ms. Sweet did not report the violations or tell Ms. Kraszewski to stop mishandling sign-in sheets. In fact, in or about April 2025, a new Protega sales rep in Miami told Plaintiff that Ms. Kraszewski had trained him and told him that he could photocopy and recycle old sign-in sheets from previous events if he needed to. Id. ¶ 54. Mr. Schulte told Plaintiff that at a work outing with Ms. Kraszewski and doctors in April 2025, Ms. Kraszewski ordered $75 cocktails for herself, for him and for one of the guests at the dinner. Id. ¶ 56. Although Ms. Sweet and Protega were aware of Ms. Kraszewski’s unlawful actions, Protega did not take any action against Ms. Kraszewski. Id. ¶ 57.
Almost immediately following her report to Ms. Sweet, Plaintiff noticed that many of her colleagues stopped responding to her communications. Id. ¶ 59. Plaintiff alleges that colleagues who had always freely communicated with her suddenly became silent and stopped returning Plaintiff’s calls and messages. Id. ¶ 60. A female colleague who started working as a Specialty Account Manager for Protega in 2024 admitted to Plaintiff that Ms. Kraszewski had instructed her to avoid interacting with Plaintiff and to be cautious around her. Id. ¶ 61. A male colleague also informed Plaintiff that Ms. Kraszewski had been badmouthing Plaintiff to him and others. Id. ¶ 62. At the same time, Ms. Kraszewski began making hostile comments about Plaintiff in front of others, such as “She pissed off
At an April 2025 conference that Protega held in Kansas, Plaintiff alleges that, seated with the group of coworkers, Ms. Kraszewski spontaneously raised the topic of doctors propositioning her at various conferences. Id. ¶¶ 65-68. Ms. Kraszewski told the group that at the NANS conference in February, one doctor had tried to hold her hand while alone with her in an elevators, and another doctor had been texting her late at night. Id. ¶ 68. Then Ms. Kraszewski mentioned that the same doctor was texting her at that very moment. Id. Ms. Kraszewski also reminded everyone at the table about the dinner with Dr. Swartz where he spoke about her sending naked pictures to his partner. Id. ¶ 69. Ms. Sweet was also present during the conversation and did nothing to stop Ms. Kraszewski from creating an uncomfortable and sexually charged environment. Id. ¶ 70.
At the training conference, each participant was charged with making a presentation to the senior leaders in attendance that showcased their drug marketing skills. Id. ¶ 71. These presentations gave senior leadership an opportunity to assess each employee and provide them with feedback. Id. During Plaintiff’s presentation, Ms. Kraszewski stated out loud but to nobody in particular, “You’ll never be a manager.” Id. ¶ 72. After the presentation, Ms. Sweet gave Plaintiff an impromptu formal review and told Plaintiff that her presentation was too wordy and that she needed to work on her presentation skills. Id. ¶ 73. After speaking to the other participants in the training conference, Plaintiff learned that none of the other employees received a formal review. Instead, they received informal and constructive feedback. Id.
In early May 2025, Protega held another conference in Tampa, Florida for Protega employees. Id. ¶ 76. On the last day of the conference, Plaintiff approached Protega COO Paul Howe about Ms. Kraszewski’s treatment of her at the training conference in Kansas in April. Plaintiff requested that
On or about May 9, 2025, Plaintiff reported to Protega’s HR department how Ms. Kraszewski had been retaliating against her since Plaintiff reported Ms. Kraszewski’s unlawful and improper behavior. Id. ¶ 84. One week later, on May 16, 2025, Plaintiff received a call from HR and Mr. Howe, accusing her of behaving inappropriately at the recent Protega conference in Tampa and of discussing the private matter of Ms. Kraszewski’s naked pictures in front of other employees. Id. ¶ 86. Protega further accused Plaintiff of spreading rumors about Ms. Kraszewski. Id. Mr. Howe then asked if there was anything else Plaintiff wanted to share. Id. ¶ 87. Plaintiff responded that she had tried to have the conversation about Ms. Kraszewski’s inappropriate behavior privately at the recent conference. Id. ¶ 88. Plaintiff further stated that Ms. Kraszewski had been having a sexual relationship with one of her peers – Mr. Schulte – for nearly a year and was giving him preferential treatment. Id. ¶ 90. Plaintiff
II. Procedural History
Plaintiff filed her Complaint August 25, 2025. ECF No. 1. Defendant filed their motion to dismiss on December 1, 2025. ECF No. 16. Plaintiff filed her Opposition on January 16, 2026. ECF No. 21. Defendant filed their Reply on February 2, 2026. ECF No. 21.
STANDARD OF REVIEW
When resolving a motion to dismiss under
DISCUSSION
I. Retaliation under the False Claims Act
The federal False Claims Act (“FCA”) provides as follows:
Any employee, contractor, or agent shall be entitled to all relief necessary to make that employee, contractor, or agent whole, if that employee, contractor, or agent is discharged, demoted, suspended, threatened, harassed, or in any other manner discriminated against in the terms and conditions of employment because of lawful acts done by the employee, contractor, agent or associated others in furtherance of an action under this section or other efforts to stop 1 or more violations of this subchapter.
31 U.S.C. § 3730 (h)(1) .
To state a claim for retaliation, a plaintiff must allege that “(1) she engaged in activity protected under the statute, (2) the employer was aware of such activity, and (3) the employer took adverse action against her because she engaged in the protected activity.” United States ex rel. Chorches v. Am. Med. Response, Inc., 865 F.3d 71, 95 (2d Cir. 2017).
Defendant Protega argues that Plaintiff has not engaged in protected activity. An employee engages in protected activity under
Defendant argues that Plaintiff has not alleged conduct that Protega failed to meet its reporting obligations under the Sunshine Act, noting that the Sunshine Act “is a reporting statute. It doesn’t limit how much money a company . . . spends on doctors; it just requires them to honestly report how much they spend.” Hart v. Publicis Touchpoint Solutions, Inc. 821 F. App’x 557, 562 (6th Cir. 2020). Defendant argues that the Sunshine Act does not require attendance sheets at conferences and instead, it requires manufacturers to track and report payments and “transfers of value” to physicians.
While not necessary to the Court’s decision on the FCA claim, the Court also finds that Plaintiff subjectively and objectively had a basis for believing Protega was in violation of the Anti-Kickback Statute (“AKS”). The AKS prohibits a person from “knowingly and willfully offer[ing] or pay[ing] any remuneration (including any kickback, bribe, or rebate) ... to purchase, lease, order, or arrange for or recommend purchasing, leasing, or ordering any good, facility, service, or item for which payment may be made ... under a Federal health care program.”
Here, the Plaintiff connects the sale of Protega’s drug RoxyBond to payments made by a federally funded healthcare program, Medicare. Compl. ¶¶ 43-44. The Complaint alleges that
Finally, the Court briefly addresses Defendant’s argument that Plaintiff’s motivation behind bringing this lawsuit is detached from the purposes of the FCA and instead was “motivated by [Plaintiff’s] own desire for a promotion and her apparent jealousy of Ms. Kraszewski.” Defendant’s Motion to Dismiss (“Deft. MTD”), at 6. In support, Defendant cites to Adiram v. Catholic Guardian Servs., No. 13-CV-6235, 2015 WL 5706935 (E.D.N.Y. Sept. 28, 2015), which found that the plaintiffs there provided no details regarding the alleged fraud. However, here, Plaintiff provided significant details about the potential fraud she witnessed by Ms. Kraszewski and others working at Protega, including Ms. Sweet and Mr. Howe. Compl. ¶¶ 48, 83. Therefore, the Court rejects Defendant’s argument. Plaintiff has plausibly alleged a claim under the FCA.
II. Retaliation Claim under New York Labor Law §740
“Under New York Labor Law (“NYLL”) § 740—the NYLL’s “whistleblower” provision—an employer cannot retaliate against an employee ... because such employee ... discloses, or threatens to disclose to a supervisor or to a public body an activity, policy or practice of the employer that the employee reasonably believes is in violation of law, rule or regulation ... or objects to, or refuses to
Defendant argues that Plaintiff does not identify the particular activities, policies or practices that Protega allegedly engaged in “because there are no PPSA or AKA violations.” Deft. MTD. at 8. However, as already detailed above, Plaintiff does plausibly allege violations of PPSA and AKA. See Sec. I. Defendant also argues that Plaintiff has failed to make out a claim under Sec. 740 because Plaintiff “has not alleged that she reasonably believed that Protega’s conduct (lack of attendance sheets at conferences, a co-worker ordering $75 cocktails or showing indecent photos of herself to a doctor) posed a substantial and specific danger to public health or safety.” Deft. MTD. at 8. Defendant misreads Sec. 740, which states in relevant part that employees are protected for disclosing “an activity, policy or practice of the employer that the employee reasonably believes is in violation of law, rule or regulation or that the employee reasonably believes poses a substantial and specific danger to the public health or safety.”
III. Sex Discrimination Claims under the NYCHRL and NYSHRL
Under the NYSHRL, “harassment is an unlawful discriminatory practice when it subjects an individual to inferior terms, conditions or privileges of employment because of the individual’s membership in one or more . . . protected categories.”
Defendant argues Plaintiff has failed to plead sex discrimination under either statute because she has alleged “paramour preference” claims, “wherein employees are treated disparately based not on their gender, but rather on a romantic relationship between an employer or supervisor and a person preferentially treated.” Qorrolli v. Metro. Dental Assocs., 124 F.4th 115, 123 (2d Cir. 2024) (internal citations and quotations omitted) (reminding that the Second Circuit has long rejected these kinds of claims as sex discrimination). Defendant argues that Plaintiff’s sex discrimination claims are just based on allegations of a sexual relationship between Ms. Kraszewski and Mr. Schulte. However, Plaintiff argues that her claims go beyond this and that she alleges a hostile work environment. In her Complaint, Plaintiff alleges Protega tolerated a highly sexualized workplace and that women who participated in sexualized behavior were favored and those who opposed such conduct were punished. Plaintiff alleges Ms. Kraszewski discussed graphic details of her sexual
IV. Retaliation under the NYSHRL and NYCHRL
“The NYSHRL historically utilized the same standard as Title VII, but [since 2019, for retaliation claims under NYSHRL] a plaintiff must establish that: (1) he or she engaged in a protected activity as that term is defined under the [state or local law], (2) his or her employer was aware that he or she participated in such activity, (3) his or her employer engaged in conduct which was reasonably likely to deter a person from engaging in that protected activity, and (4) there is a causal connection between the protected activity and the alleged retaliatory conduct.” Edelman v. NYU Langone Health Sys., 141 F.4th 28, 53 (2d Cir. 2025).
As before, Defendant argues that Plaintiff’s retaliation claims under NYSHRL and NYCHRL fail because she did not allege protected activity. The Court has already held that, at this stage, Plaintiff’s claim goes beyond a paramour preference. When Plaintiff complained to her supervisor, HR, and the COO, about the sexually charged workplace, she was treated worse and was eventually terminated. Therefore, the Court finds Plaintiff has plausibly plead retaliation under NYSHRL and NYCHRL.
CONCLUSION
SO ORDERED.
Dated: August 10, 2026
New York, New York
ANDREW L. CARTER, JR.
United States District Judge